Topical pain relief cream formulation in the management of knee osteoarthritis: a randomized, double-blind and placebo-controlled clinical study
DOI:
https://doi.org/10.18203/issn.2455-4510.IntJResOrthop20262921Keywords:
Topical pain relief cream formulation, Osteoarthritis, Joint pain, Joint swellingAbstract
Background: Topical formulations provide localized pain relief with improved safety profile. This study evaluated the efficacy and safety of a topical pain relief cream formulation in subjects with knee OA compared with placebo.
Methods: This multicentric, randomized, double-blind, placebo-controlled clinical study analyzed 335 subjects with clinically diagnosed knee OA who received either a topical pain relief cream formulation (Group B, n=166) or placebo (Group A, n=169) for 28 days. Primary efficacy endpoints were knee joint pain assessed using visual analog scale (VAS) and joint swelling. Secondary endpoints included modified Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores, knee joint tenderness, warmth, onset and duration of action, global assessments, and safety.
Results: The topical pain relief cream formulation demonstrated significantly greater reductions in knee joint pain (19.7-21.4% at day 14 and 38.3-38.6% at day 28, p<0.001) and swelling (p<0.001) compared with placebo. Modified WOMAC scores for pain, stiffness, and difficulty in movements were also significantly (p<0.05) improved than placebo. The formulation demonstrated a significantly (p<0.001) faster onset and longer duration of action in terms of pain relief. Knee tenderness and rescue medication use were significantly (p<0.05) reduced. The formulation was well tolerated with no treatment-related adverse events (AEs).
Conclusions: The topical pain relief cream formulation significantly reduced knee joint pain and swelling while improving joint function. These findings support its potential as a safe, fast acting and effective topical therapy for managing knee OA.
References
Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. Part I. Arthrit Rheum. 1995;38(11):1535-40.
Alcaraz MJ, Megías J, García-Arnandis I, Clérigues V, Guillén MI. New molecular targets for the treatment of osteoarthritis. Biochem Pharmacol. 2010;80(1):13-21.
Long H, Liu Q, Yin H, Wang K, Diao N, Zhang Y, et al. Prevalence trends of site-specific osteoarthritis from 1990 to 2019: Findings from the global burden of disease study 2019. Arth Rheumatol. 2022;74(7):1172-83.
Sethi V, Anand C, Della Pasqua O. Clinical assessment of osteoarthritis pain: Contemporary scenario, challenges, and future perspectives. Pain Ther. 2024;13(3):391-408.
Courties A, Kouki I, Soliman N, Mathieu S, Sellam J. Osteoarthritis year in review 2024: Epidemiology and therapy. Osteoarthritis Cartilage. 2024;32(11):1397-404.
Holderbaum D, Haqqi TM, Moskowitz RW. Genetics and osteoarthritis: exposing the iceberg. Arthritis Rheum 1999;42(3):397-405.
Mow VC, Setton LA, Fuilak F. Mechanical factors in articular cartilage and their role in osteoarthritis. In: Kuettner KE, Recommendations for hip and knee OA management Goldberg VM, editors. Osteoarthritic disorders. Rosemont (IL): American Academy of Orthopaedic Surgeons. 1995;147-72.
Poole AR. Imbalances of anabolism and catabolism of cartilage matrix components in osteoarthritis. In: Kuettner KE, Goldberg VM, editors. Osteoarthritic disorders. Rosemont (IL): American Academy of Orthopaedic Surgeons. 1995;247-60.
Primorac D, Molnar V, Rod E, Jeleč Ž, Čukelj F, Matišić V, et al. Knee osteoarthritis: A review of pathogenesis and state-of-the-art non-operative therapeutic considerations. Genes (Basel). 2020;11(8):854.
Mora JC, Przkora R, Cruz-Almeida Y. Knee osteoarthritis: pathophysiology and current treatment modalities. J Pain Res. 2018;11:2189-96.
Perrot S, Trouvin AP, Bouhassira D. Three dimensions of pain in osteoarthritis: development and validation of the Osteoarthritis Symptom Inventory Scale. Pain. 2023;164(7):1566-77.
McDougall JJ. Osteoarthritis is a neurological disease-an hypothesis. Osteoarthr Cartil Open. 2019;1(1-2):100005.
Meng Y, Shen HL. Role of N-methyl-D-aspartate receptor NR2B subunit in inflammatory arthritis-induced chronic pain and peripheral sensitized neuropathic pain: A systematic review. J Pain Res. 2022;15:2005-13.
Nijs J, Malfliet A, Nishigami T. Nociplastic pain and central sensitization in patients with chronic pain conditions: a terminology update for clinicians. Braz J Phys Ther. 2023;27(3):100518.
Miyamoto S, Iida S, Miyashita T, Katou K, Kawarai Y, Nakamura J, et al. Mechanism of chronic pain of symptomatic hip osteoarthritis by association of its distribution, nociceptive, neuropathic, nociplastic, or mixed-pain screening, and the prevalence of lumbar spinal stenosis: A cross-sectional study. Clin J Pain. 2021;38(2):77-87.
Meng Z, Huang R. Topical treatment of degenerative knee osteoarthritis. Am J Med Sci. 2018;355:6-12.
Guo J, Hu X, Wang J, Yu B, Li J, Chen J, et al. Safety and efficacy of compound methyl salicylate liniment for topical pain: A multicenter real-world study in China. Front Pharmacol. 2022;13:1015941.
Laslett LL, Quinn SJ, Darian-Smith E, Kwok M, Fedorova T, Körner H, et al. Treatment with 4Jointz reduces knee pain over 12 weeks of treatment in patients with clinical knee osteoarthritis: a randomised controlled trial. Osteoarthritis Cartilage. 2012;20(11):1209-16.
da Costa BR, Saadat P, Basciani R, Agarwal A, Johnston BC, Jüni P. Visual Analogue Scale has higher assay sensitivity than WOMAC pain in detecting between-group differences in treatment effects: a meta-epidemiological study. Osteoart Cartilage. 2021;29(3):304-12.
Wilk KE, Mangine RE, Tersakjs J, Hasselford K. The effects on knee swelling, range of motion and pain using a commercially available hot/cold contrast device in a rehabilitation and sports medicine setting. Int J Sports Phys Ther. 2022;17(5):924-30.
Center For Rheumatic Disease. Health Instruments. Avaible at: http://rheumatologyindia.org/research_health.htm Accessed on 29 March 2026.
Doyle DV, Dieppe PA, Scott J, Huskisson EC. An articular index for the assessment of osteoarthritis. Ann Rheum Dis. 1981;40(1):75-8.
Doyle DV, Dieppe PA, Scott J, Huskisson EC. An articular index for the assessment of osteoarthritis. Ann Rheum Dis 1981;40(1):75-8.
Brahmachari B, Chatterjee S, Ghosh A. Efficacy and safety of diacerein in early knee osteoarthritis: a randomized placebo-controlled trial. Clin Rheumatol. 2009;28(10):1193-8.
Abolhassanzadeh Z, Aflaki E, Yousefi G, Mohagheghzadeh A. Randomized clinical trial of peganum oil for knee osteoarthritis. J Evid Based Complementary Altern Med. 2015;20(2):126-31.
Aspalli S, Shetty VS, Devarathnamma MV, Nagappa G, Archana D, Parab P. Evaluation of antiplaque and antigingivitis effect of herbal mouthwash in treatment of plaque induced gingivitis: A randomized, clinical trial. J Indian Soc Periodontol. 2014;18(1):48-52.
Talha, Ali A, Mohapatra S, Siddiqui A, Farooq U, Shamim A, et al. A pharmaco-technical investigation of oxaprozin and gaultheria oil nanoemulgel: a combination therapy. RSC Pharm. 2024;1(3):484497.
Mohsenzadeh A, Karimifar M, Soltani R, Hajhashemi V. Evaluation of the effectiveness of topical oily solution containing frankincense extract in the treatment of knee osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial. BMC Res Notes. 2023;16(1):28.
Safayhi H, Mack T, Sabieraj J, Anazodo MI, Subramanian LR, Ammon HP. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther. 1992;261(3):1143-6.
Sailer ER, Subramanian LR, Rall B, Hoernlein RF, Ammon HP, Safayhi H. Acetyl-11-keto-beta-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity. Br J Pharmacol. 1996;117(4):615-8.
Lalithakumari K, Krishnaraju AV, Sengupta K, Subbaraju GV, Chatterjee A. Safety and toxicological evaluation of a novel, standardized 3-O-acetyl-11-keto-beta-boswellic acid (AKBA)-enriched Boswellia serrata extract (5-Loxin(R)). Toxicol Mech Methods. 2006;16(4):199-226.
Wang Q, Pan X, Wong HH, Wagner CA, Lahey LJ, Robinson WH, et al. Oral and topical boswellic acid attenuates mouse osteoarthritis. Osteoarthritis Cartilage. 2014;22(1):128-32.
Demina NB, Bachrushina EO, Sukoyan GV, Khvitia NG. Anti-inflammatory efficacy of topical formulation of Boswellia serrata in experimental paw edema. Sch Acad J Pharm. 2019;8(11):1.
Guedes V, Castro JP, Brito I. Topical capsaicin for pain in osteoarthritis: A literature review. Reumatol Clin (Engl Ed). 2018;14(1):40-5.
Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American college of rheumatology/arthritis foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2020;72(2):149-62.
Shtroblia V, Petakh P, Kamyshna I, Halabitska I, Kamyshnyi O. Recent advances in the management of knee osteoarthritis: a narrative review. Front Med (Lausanne). 2025;12:1523027.
Cameron M, Chrubasik S. Topical herbal therapies for treating osteoarthritis. Cochrane Database Syst Rev. 2013(5):CD010538.
Downloads
Published
How to Cite
Issue
Section
